Skip to content
Medical Health Aged Care

RACGP backs listing of smoking cessation medicine

Royal Australian College of GPs 2 mins read

The Royal Australian College of GPs (RACGP) has thrown its support behind a new drug that can help people quit smoking.

It comes following Australia’s chief medicine and therapeutic regulator, the Therapeutic Goods Administration, receiving a private application to schedule the drug Cytisine as a potential medicine for smoking cessation.

RACGP President Dr Nicole Higgins said the medicine could make a real difference.

“There has never been a more important time to help people quit nicotine products, including cigarettes and nicotine vaping products,” she said.

“Unfortunately, some of the approved medications for smoking cessation, including nicotine replacement therapy options like patches, are set to be removed from the Pharmaceutical Benefits Scheme in a few months’ time. We have asked federal Health and Aged Care Minister Mark Butler to step in to prevent the possible removal of nicotine patches from the public scheme. Otherwise, we will regress in our fight against nicotine use in Australia.

“In the meantime, approving this new medicine Cytisine, will also play a key role in helping patients quit nicotine. At a time where our world-leading efforts to reduce smoking cessation are under threat from the spectre of more and more people, including young people, taking up nicotine vaping, we need additional tools in our smoking and vaping cessation toolbox.”

Dr Higgins said that Cytisine was not an unknown quantity.

“This medicine has a proven track record in smoking cessation, it has minimal side effects, and it is sorely needed to tackle the ongoing battle of nicotine addiction, particularly among our youth,” she said.

“It has been safely used in eastern Europe for smoking cessation since the 1960s. So, we support the application for this medicine to be scheduled as a smoking cessation aid and we continue to urge the Government to step in and prevent the removal of nicotine patches from the Pharmaceutical Benefits Scheme.

“If you, or someone you know, wants to quit nicotine – please consult with your GP. We have the strategies, advice, and medicines available to help you along every step of the way. Once you quit smoking, you will feel so much better, and so relieved you took that first step of booking an appointment with your trusted GP. It could be the best decision you ever make.”

~ENDS

RACGP spokespeople are available for interview.


About us:

About the RACGP

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

 

Email: media@racgp.org.au (we will respond promptly to all media inquiries).

Follow us on Twitter: @RACGP and Facebook.

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.